| SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT |
The
following table summarizes segment financial information by business segment for the year ended and at March 31, 2026:
SCHEDULE
OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT
| (in thousands) | |
Beyond Air | | |
Beyond Cancer | | |
NeuroNos | | |
Total | |
| Capital expenditures | |
$ | 1,024 | | |
$ | - | | |
$ | 2 | | |
$ | 1,026 | |
| | |
| | | |
| | | |
| | | |
| | |
| Revenues | |
$ | 7,679 | | |
$ | - | | |
$ | - | | |
$ | 7,679 | |
| Cost of revenues | |
| (7,427 | ) | |
| - | | |
| - | | |
| (7,427 | ) |
| Research and development | |
| (7,677 | ) | |
| (1,170 | ) | |
| (1,394 | ) | |
| (10,241 | ) |
| Selling, general, and administrative | |
| (15,418 | ) | |
| (2,207 | ) | |
| (1,430 | ) | |
| (19,055 | ) |
| Loss from operations | |
| (22,843 | ) | |
| (3,377 | ) | |
| (2,824 | ) | |
| (29,044 | ) |
| Interest and finance expense | |
| (3,515 | ) | |
| - | | |
| - | | |
| (3,515 | ) |
| Other non-operating income/(expense) | |
| (1,668 | ) | |
| (323 | ) | |
| 216 | | |
| (1,775 | ) |
| Net loss before income taxes | |
$ | (28,026 | ) | |
$ | (3,700 | ) | |
$ | (2,608 | ) | |
$ | (34,334 | ) |
| Operating activities included in net loss: | |
| | | |
| | | |
| | | |
| | |
| Depreciation and amortization | |
$ | 3,228 | | |
$ | 23 | | |
$ | - | | |
$ | 3,251 | |
| Stock-based compensation expense | |
$ | 3,813 | | |
$ | 1,373 | | |
$ | 96 | | |
$ | 5,282 | |
| | |
| | | |
| | | |
| | | |
| | |
| Cash used in operations | |
$ | (14,775 | ) | |
$ | (1,314 | ) | |
$ | (2,055 | ) | |
$ | (18,144 | ) |
| Cash used in (provided by) investing | |
| (4,660 | ) | |
| 988 | | |
| (2 | ) | |
| (3,674 | ) |
| Cash provided by financing | |
| 28,390 | | |
| - | | |
| 700 | | |
| 29,090 | |
| Impact of exchange rates | |
| 228 | | |
| 164 | | |
| (198 | ) | |
| 194 | |
| Net change for the year | |
$ | 9,183 | | |
$ | (162 | ) | |
$ | (1,555 | ) | |
$ | 7,466 | |
The
following table summarizes segment financial information by business segment for the year ended and at March 31, 2025:
| (in thousands) | |
Beyond Air | | |
Beyond Cancer | | |
NeuroNos | | |
Total | |
| Capital expenditures | |
$ | 5,859 | | |
$ | 24 | | |
$ | - | | |
$ | 5,883 | |
| | |
| | | |
| | | |
| | | |
| | |
| Revenues | |
$ | 3,705 | | |
$ | - | | |
$ | - | | |
$ | 3,705 | |
| Cost of revenues | |
| (5,368 | ) | |
| - | | |
| - | | |
| (5,368 | ) |
| Research and development | |
| (13,780 | ) | |
| (3,062 | ) | |
| (15 | ) | |
| (16,857 | ) |
| Selling, general, and administrative | |
| (19,565 | ) | |
| (6,344 | ) | |
| (108 | ) | |
| (26,017 | ) |
| Loss from operations | |
| (35,008 | ) | |
| (9,406 | ) | |
| (123 | ) | |
| (44,537 | ) |
| Interest and finance expense | |
| (3,019 | ) | |
| - | | |
| - | | |
| (3,019 | ) |
| Other non-operating income/(expense) | |
| (1,132 | ) | |
| 209 | | |
| - | | |
| (923 | ) |
| Net loss before income taxes | |
$ | (39,159 | ) | |
$ | (9,197 | ) | |
$ | (123 | ) | |
$ | (48,479 | ) |
| Operating activities included in net loss: | |
| | | |
| | | |
| | | |
| | |
| Depreciation and amortization | |
$ | 3,143 | | |
$ | 61 | | |
$ | - | | |
$ | 3,204 | |
| Stock-based compensation expense | |
$ | 7,920 | | |
$ | 1,154 | | |
$ | 72 | | |
$ | 9,146 | |
| | |
| | | |
| | | |
| | | |
| | |
| Cash used in operations | |
$ | (29,599 | ) | |
$ | (8,619 | ) | |
$ | - | | |
$ | (38,218 | ) |
| Cash provided by investing | |
| 11,844 | | |
| 3,061 | | |
| - | | |
| 14,905 | |
| Cash provided by financing | |
| 14,646 | | |
| - | | |
| 2,000 | | |
| 16,646 | |
| Impact of exchange rates | |
| (39 | ) | |
| (6 | ) | |
| - | | |
| (45 | ) |
| Net change for the year | |
$ | (3,148 | ) | |
$ | (5,564 | ) | |
$ | 2,000 | | |
$ | (6,712 | ) |
The
following table summarizes financial information by business segment at March 31, 2026:
| (in thousands) | |
Beyond Air | | |
Beyond Cancer | | |
NeuroNos | | |
Total | |
| Cash, cash equivalents and marketable securities | |
$ | 10,140 | | |
$ | 1,043 | | |
$ | 458 | | |
$ | 11,641 | |
| All other assets | |
| 23,901 | | |
| (219 | ) | |
| 62 | | |
| 23,744 | |
| Total assets | |
$ | 34,041 | | |
$ | 824 | | |
$ | 520 | | |
$ | 35,385 | |
| Total liabilities | |
| (28,224 | ) | |
| (378 | ) | |
| (573 | ) | |
| (29,175 | ) |
| Net assets | |
$ | 5,817 | | |
$ | 446 | | |
$ | (53 | ) | |
$ | 6,210 | |
| Non-controlling interest | |
$ | - | | |
$ | 64 | | |
$ | 20 | | |
$ | 84 | |
The
following table summarizes financial information by business segment at March 31, 2025:
| (in thousands) | |
Beyond Air | | |
Beyond Cancer | | |
NeuroNos | | |
Total | |
| Cash, cash equivalents and marketable securities | |
$ | 2,750 | | |
$ | 2,167 | | |
$ | 2,000 | | |
$ | 6,917 | |
| All other assets | |
| 22,116 | | |
| 1,029 | | |
| - | | |
| 23,145 | |
| Total assets | |
$ | 24,866 | | |
$ | 3,196 | | |
$ | 2,000 | | |
$ | 30,062 | |
| Total liabilities | |
| (15,082 | ) | |
| (589 | ) | |
| (50 | ) | |
| (15,721 | ) |
| Net assets | |
$ | 9,784 | | |
$ | 2,607 | | |
$ | 1,950 | | |
$ | 14,341 | |
| Non-controlling interest | |
$ | - | | |
$ | 529 | | |
$ | 229 | | |
$ | 758 | |
|